Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BANCAP HC vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BANCAP HC contains hydrocodone, a mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, to reduce pain and fever.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Management of moderate to moderately severe pain,Off-label: cough suppression (hydrocodone component)
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Each 5 m L contains hydrocodone bitartrate 5 mg and acetaminophen 500 mg. For moderate to moderately severe pain: 1 tablet (or 5 m L suspension) every 4 to 6 hours as needed; maximum single dose: 2 tablets (10 m L); maximum daily dose: 8 tablets (40 m L) due to acetaminophen limit.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal elimination half-life: 3.8 hours (range 3.3–4.4 h) for hydrocodone; clinical context: requires dosing every 4–6 hours to maintain analgesic effect, with potential accumulation in renal impairment.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Hydrocodone is metabolized by CYP2D6 and CYP3A4 to hydromorphone (active) and norhydrocodone; acetaminophen is primarily metabolized by glucuronidation and sulfation, with minor CYP2E1 oxidation to NAPQI.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Renal elimination of unchanged drug and metabolites: 90% (60% as glucuronide conjugates, 10% as unchanged drug, 5% as cysteine and mercapturic acid conjugates); biliary/fecal: 5%; the remainder as other metabolites. Renal clearance of hydrocodone is dose-dependent.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
20–30% bound to plasma proteins (primarily albumin).
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Vd: 3.5–4.0 L/kg; indicates extensive tissue distribution with high penetration into central nervous system.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Oral: 70% (first-pass metabolism reduces bioavailability; range 60–80%).
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
For GFR 30-50 m L/min: reduce dose to 75% of normal, extend interval to every 6 hours. For GFR <30 m L/min: avoid use; if necessary, use 50% of normal dose every 8 hours with careful monitoring.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: start at 50% of normal dose, titrate cautiously, maximum daily acetaminophen 2000 mg. Child-Pugh Class C: contraindicated.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Weight-based: hydrocodone 0.1-0.2 mg/kg/dose (max 10 mg/dose) every 4-6 hours as needed; acetaminophen 10-15 mg/kg/dose (max 75 mg/kg/day). For BANCAP HC 5-500: 0.1-0.2 m L/kg/dose (max 10 m L/dose) every 4-6 hours.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Initiate at 50% of adult dose (e.g., half tablet or 2.5 m L) every 6 hours; maximum daily acetaminophen 3000 mg; monitor renal function and avoid in frailty with GFR <30.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity (acetaminophen).
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Respiratory depression, drug interaction with CNS depressants, risk of hypotension, risk of serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, hepatotoxicity (acetaminophen), opioid-induced hyperalgesia, dependency/tolerance.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Hypersensitivity to hydrocodone or acetaminophen, significant respiratory depression, acute or severe bronchial asthma, gastrointestinal obstruction (including paralytic ileus), severe hepatic impairment (acetaminophen).
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Avoid alcohol completely. Grapefruit juice may increase hydrocodone levels; caution advised. High-fat meals may delay absorption of hydrocodone, but no specific food restrictions.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
BANCAP HC contains hydrocodone and acetaminophen. Hydrocodone: Risk not fully established; first trimester: potential association with congenital malformations (limited data); second and third trimesters: prolonged use may cause neonatal opioid withdrawal syndrome and respiratory depression at delivery. Acetaminophen: Generally considered low risk at therapeutic doses; prolonged high-dose use may be associated with fetal adverse effects.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Hydrocodone: Excreted in breast milk; relative infant dose estimated <5% of maternal weight-adjusted dose; M/P ratio not well characterized. Monitor infant for sedation, respiratory depression, and poor feeding. Acetaminophen: Compatible with breastfeeding; minimal excretion.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
No specific dose adjustments established for pregnancy. Increased clearance during pregnancy may require dose adjustments for pain relief; cautious use at lowest effective dose for shortest duration due to fetal risks.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
BANCAP HC is a combination of hydrocodone (an opioid) and acetaminophen. Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen dose should not exceed 4 g in adults. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; poor metabolizers may have reduced effect. Avoid concurrent use with other CNS depressants, including alcohol. Use with caution in patients with respiratory compromise, head injury, or biliary tract disorders.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Take this medication exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Acetaminophen is also present in many over-the-counter products; check labels to avoid exceeding 4000 mg per day.,Do not consume alcohol while taking this medication; risk of liver damage and increased sedation.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Do not stop abruptly; withdrawal symptoms may occur. Consult your doctor for a tapering schedule.,Store securely away from children; accidental ingestion can be fatal.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BANCAP HC vs ALFENTANIL, answered by our medical review team.
BANCAP HC is a Opioid Analgesic that works by BANCAP HC contains hydrocodone, a mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, to reduce pain and fever.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BANCAP HC and ALFENTANIL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BANCAP HC is: Each 5 m L contains hydrocodone bitartrate 5 mg and acetaminophen 500 mg. For moderate to moderately severe pain: 1 tablet (or 5 m L suspension) every 4 to 6 hours as needed; maximum single dose: 2 tablets (10 m L); maximum daily dose: 8 tablets (40 m L) due to acetaminophen limit.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BANCAP HC and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BANCAP HC is classified as Category C. BANCAP HC contains hydrocodone and acetaminophen. Hydrocodone: Risk not fully established; first trimester: potential association with congenital malformations (limited data); seco. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.